Hana Biosciences files for $75 million stock shelf

By Jennifer Chiou

New York, April 19 - Hana Biosciences, Inc. filed for a $75 million stock shelf in an S-3 registration with the Securities and Exchange Commission.

The San Francisco development-stage biopharmaceutical company is focused on cancer products and has three compounds in early-stage development: Talotrexin for solid tumor cancers and hematological malignancies, oral spray Zensana for chemotherapy-induced nausea and vomiting, and IPdR for brain cancer.

Proceeds will be used for clinical trials, research and development, sales and marketing, and general and administrative expenses.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.